KalVista Pharmaceuticals(KALV)

Focus: KalVista is a public specialty pharma company focused on ophthalmology and neurology with a small-cap structure (201-500 employees) headquartered in Framingham, MA. As of June 2026, the company was acquired by Chiesi Group for $1.64–$1.9 billion.

Ophthalmology Neurology

Profile data last refreshed 37m ago · AI intelligence enriched 2mo ago

Funding Stage

PUBLIC

Employees

201-500

Open Jobs

About KalVista Pharmaceuticals

AI assessmentNot Hiring

No open roles listed right now. Follow KalVista Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.

Generated by Claude from KalVista Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Data completeness

6/9 — Partial

Company HealthStrong

Pipeline

Late-stage

4 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$50M

Key Products

AMICAR

Anemia

$60K Part D

LOE Approaching

Sole revenue driver (100% of company revenue) but losing exclusivity; limited Part D utilization suggests commoditization risk.

Help build intelligence for KalVista Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pipeline & Clinical Trials

Sebetralstat

Hereditary Angioedema

N/A

Clinical Trials (1)

NCT06628713Treatment of Angioedema Attacks in Adolescent and Adult Patients 12 Years and Older With HAE Type I or II With Sebetralstat

N/A

Inapplicable

Hereditary Angioedema

N/A

Clinical Trials (1)

NCT07009262A Study Observing US Patients With HAE Type I or II Who Take Icatibant to Treat HAE Attacks

N/A

Sebetralstat

Hereditary Angioedema

N/A

Clinical Trials (2)

NCT07654829Safety and Effectiveness of Sebetralstat (KVD900) for Short-Term Prophylaxis Before Procedures in People With Hereditary Angioedema (KONTROL)

Phase 4

NCT07216378Treatment of Angioedema Attacks in Pediatric (Ages 2-11) Post-Trial and Naive Patients With HAE With Sebetralstat

KVD900

Hereditary Angioedema

PHASE_1

Clinical Trials (1)

NCT04349800A Single Dose Safety, Tolerability, Pharmacokinetic and Food Effect Study of KVD900 (Sebetralstat) in Healthy Volunteers

Phase 1

KVD824 Prototype 1 modified-release tablet

Hereditary Angioedema

PHASE_1

Clinical Trials (1)

NCT05118958Phase 1 Crossover Study in Healthy Subjects to Evaluate the PK Profile of KVD824 Following Single and Multiple Doses of Modified Release (MR) Formulations

Phase 1

KVD001 Injection

Diabetic Macular Edema

PHASE_1

Clinical Trials (1)

NCT02193113A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DME

Phase 1

KVD824

Hereditary Angioedema

PHASE_1

Clinical Trials (1)

NCT05178355A Single and Multiple Doses Safety, Tolerability, Pharmacokinetics and Food Effect Study of KVD824 in Healthy Volunteers

Phase 1

KVD900

Hereditary Angioedema

PHASE_2

Clinical Trials (1)

NCT04208412A Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) in the On-demand Treatment of Angioedema Attacks in Adult Subjects With Hereditary Angioedema Type I or II

Phase 2

KVD001 Injection

Diabetic Macular Edema

PHASE_2

Clinical Trials (1)

NCT03466099Study of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects With Center-involving Diabetic Macular Edema (ciDME)

Phase 2

KVD824

Angioedema, Hereditary, Types I and II

PHASE_2

Clinical Trials (1)

NCT05055258A Trial to Evaluate the Efficacy and Safety of Different Doses of KVD824 for Prophylactic Treatment of HAE Type I or II

Phase 2

KVD900 600 mg

Hereditary Angioedema

PHASE_3

Clinical Trials (1)

NCT05505916An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)

Phase 3

Placebo

Hereditary Angioedema

PHASE_3

Clinical Trials (1)

NCT05259917A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)

Phase 3

KVD900 150 mg

Hereditary Angioedema

PHASE_3

Clinical Trials (1)

NCT06467084Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II

Phase 3

KVD900 600 mg

Hereditary Angioedema

PHASE_3

Clinical Trials (1)

NCT05511922PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial

Phase 3

Interview Prep Quick Facts

Portfolio: 42 approved products, 15 clinical trials

Top TAs: Hematology, Gastroenterology, Neurology

Publications: 28 in PubMed

SEC Filings: 2 available

Portfolio Health

Pre-Launch1 (2%)

Growth1 (2%)

Peak1 (2%)

LOE Approaching1 (2%)

Post-LOE38 (90%)

42 total products

Therapeutic Area Focus

21 marketed

2 marketed

2 marketed

1 marketed

1 marketed

Financials (FY2025)

Revenue

$50M

R&D Spend

$86M(172%)23%

Net Income

-$93M

Cash

Risk Signals

No explicit layoff announcements in data, but post-acquisition status and AMICAR revenue collapse strongly suggest workforce reductions or restructuring in Q3–Q4 2026.

Acquisition integration, AMICAR cliff, and cash burn create high restructuring probability; role security is uncertain absent Phase 3 success for KVD900.